Fact-checked by Grok 2 weeks ago

CD23

CD23, also known as FcεRII, is the low-affinity receptor for immunoglobulin E (IgE), a type II transmembrane glycoprotein primarily expressed on B cells, where it regulates IgE synthesis and immune responses.^[1] Encoded by the FCER2 gene on chromosome 19p13.3, CD23 features a C-type lectin-like extracellular domain that binds IgE with low affinity (K_D ≈ 10⁻⁶–10⁻⁷ M) and also interacts with CD21 (complement receptor 2), enabling simultaneous ligand binding to modulate IgE homeostasis.^[2] It exists in two isoforms, CD23a and CD23b, differing in their N-terminal cytoplasmic tails, which influence signaling and endocytosis.^[3] CD23's structure includes a stalk region with leucine zipper motifs that facilitate trimerization, a single transmembrane helix, and a short cytoplasmic domain, allowing it to function as both a membrane-bound receptor and a soluble form upon proteolytic cleavage by enzymes like ADAM10.^[3] Soluble CD23 fragments (e.g., 37 kDa, 33 kDa) act as mitogenic factors, promoting B-cell growth and cytokine release, such as IL-1α and nitric oxide, while membrane-bound CD23 enhances antigen presentation via interactions with MHC class II and integrins like αvβ3.^[3] Expression is upregulated by interleukin-4 (IL-4), CD40 ligation, and Epstein-Barr virus infection, primarily on B lymphocytes, monocytes, and dendritic cells.^[1] In immunology, CD23 exerts dual regulatory effects on IgE: trimeric forms upregulate IgE production through CD21 cross-linking on follicular dendritic cells, whereas monomeric or cleaved forms inhibit it, contributing to feedback control in allergic responses.^[2] It also supports B-cell differentiation and is implicated in pathogen defense, such as antimycobacterial activity in macrophages.^[3] Clinically, elevated soluble CD23 levels serve as a prognostic marker in chronic lymphocytic leukemia (CLL) and are associated with autoimmune diseases like rheumatoid arthritis and systemic lupus erythematosus (SLE).^[3] Therapeutic targeting, such as with anti-CD23 monoclonal antibodies like lumiliximab, has shown promise in treating CLL and allergic conditions by modulating IgE regulation.^[3]

Molecular biology

Gene

The FCER2 gene, encoding the low-affinity IgE receptor CD23, is situated on the short arm of human chromosome 19 at cytogenetic band p13.2. It spans approximately 13 kb of genomic DNA and comprises 11 exons.^[4]^[5]^[1] Transcription from the FCER2 gene yields an mRNA transcript of approximately 1.7 kb, which encodes a 321-amino acid precursor protein that undergoes processing to form the mature CD23 glycoprotein.^[1] Alternative splicing and differential promoter usage produce isoforms such as CD23a and CD23b, differing in their N-terminal sequences.^[4] The FCER2 gene exhibits evolutionary conservation across mammalian species, with orthologs in mice designated as Fcer2a and Fcer2b, which display high sequence similarity to the human gene particularly in the region encoding the extracellular domain.^[4] A notable polymorphism in FCER2 is the R62W single nucleotide polymorphism (rs2228137) in exon 4, which results in an amino acid substitution that confers resistance to proteolytic cleavage and has been associated with altered CD23 function in immune responses.^[6]

Protein structure and isoforms

CD23, also known as FcεRII, is a type II transmembrane glycoprotein encoded by the FCER2 gene located on chromosome 19p13.2. The canonical isoform, CD23a, consists of 321 amino acids and features a short N-terminal cytoplasmic tail of 23 amino acids, a hydrophobic transmembrane domain spanning 23 amino acids (residues 24–46), and a large extracellular region comprising approximately 275 amino acids. The extracellular domain includes a stalk region rich in charged residues and leucine zipper motifs that facilitate oligomerization, followed by a C-type lectin homology domain (also called the lectin domain) of about 150 amino acids at the C-terminus (residues 172–321).^[7]^[8]^[1] The lectin domain adopts a C-type lectin fold characterized by a β-sheet-rich structure with eight β-strands arranged in two antiparallel sheets and two α-helices, as revealed by nuclear magnetic resonance spectroscopy and subsequent crystal structures. Although structurally homologous to calcium-dependent C-type lectins, CD23 exhibits calcium-independent ligand binding, with its two potential calcium-binding sites remaining unoccupied in the apo form and showing only minor conformational adjustments upon calcium coordination. The stalk region's leucine zipper-like repeats enable the formation of trimers or higher-order oligomers on the cell surface, which are crucial for multivalent interactions.^[9]^[10] Two isoforms of CD23 arise from alternative splicing of the FCER2 transcript: CD23a, which is constitutively expressed primarily on B cells with a 23-amino-acid cytoplasmic tail containing a tyrosine-based endocytosis motif, and CD23b, an inducible form upregulated by interleukin-4 (IL-4) or CD40 ligation in B cells and other leukocytes, featuring a 29-amino-acid cytoplasmic tail due to a 6-amino-acid insertion near the N-terminus. Both isoforms share identical extracellular and transmembrane regions, allowing similar membrane-bound functions, but differ in intracellular signaling and trafficking; for instance, CD23a associates with the Fyn tyrosine kinase and undergoes efficient clathrin-mediated endocytosis via AP-2 adaptor binding.^[4]^[8]^[11] Both isoforms can generate soluble forms (sCD23) through proteolytic shedding by metalloproteases such as ADAM10, which cleaves at specific sites near the transmembrane domain (e.g., between Ala80 and Leu81 or Arg101 and Ser102), yielding fragments of 25–45 kDa, including a predominant 37-kDa species. These soluble fragments retain the lectin domain and stalk elements, often forming trimers that preserve ligand-binding capacity, though with reduced avidity compared to the membrane-bound form. Smaller derivatives, such as 16-kDa fragments from further cleavage (e.g., at Ser155/Ser156), have been observed in certain contexts but are less common.^[12]^[13]^[4]

Expression and regulation

Cellular expression

CD23 is predominantly expressed on the surface of mature B cells, including naive and germinal center subsets, as well as on activated macrophages, eosinophils, follicular dendritic cells, and platelets.^[14]^[15] In contrast, expression is low or absent on T cells, plasma cells, and resting monocytes.^[16]^[17] However, CD23 can be upregulated on specific subsets, such as IgG1+ memory B cells, particularly in the context of type 2 immune responses associated with allergies.^[18] In terms of tissue distribution, CD23 is primarily found in lymphoid organs, including the spleen and lymph nodes, where it is associated with B cell-rich areas and follicular structures.^[3] It is also present on mucosal surfaces, such as in the intestinal epithelium, and can appear in the skin during inflammatory conditions.^[3]^[19] The pattern of CD23 expression is largely similar between humans and mice, with both species showing predominant localization on B cells, activated macrophages, and follicular dendritic cells.^[20] However, glycan-binding capabilities of CD23 vary across mammalian species; human CD23 shows no detectable binding to sugars, while mouse CD23 exhibits binding that is weaker than in species like cows.^[21] Expression on human B cells, for instance, can be induced by cytokines such as IL-4.^[22]

Regulation of expression

The expression of CD23 is tightly regulated at multiple levels, including transcriptional, post-transcriptional, post-translational, and developmental stages, ensuring appropriate control in immune responses.^[23] Interleukin-4 (IL-4) is a key cytokine that upregulates CD23 expression in B cells and monocytes through activation of the STAT6 signaling pathway, which promotes transcription of the FCER2 gene and preferentially induces the CD23b isoform.^[24]^[25] In contrast, interferon-gamma (IFN-γ) counteracts this by inhibiting IL-4-induced STAT6 activation and downregulating CD23 expression, thereby suppressing the overall levels of both membrane-bound and soluble forms.^[26]^[27] Post-transcriptional regulation involves microRNAs (miRNAs) that target FCER2 mRNA to suppress its stability and translation; for instance, miR-24, miR-30b, and miR-142-3p have been shown to reduce CD23 expression in macrophages and dendritic cells.^[28] Epigenetic modifications also play a critical role, with increased histone H3 acetylation at the CD23b promoter correlating strongly with enhanced transcriptional activity and expression levels.^[29]^[30] Post-translational control occurs through proteolytic shedding, where the metalloprotease ADAM10 cleaves the extracellular domain of membrane-bound CD23, releasing soluble CD23 (sCD23) and thereby reducing surface expression; this process is upregulated under inflammatory conditions, such as exposure to IL-4 or lipopolysaccharide.^[31]^[32] During B cell development, CD23 expression is high on immature transitional B cells, particularly the CD23+ subset, which supports their survival and proliferation, but it is downregulated as these cells differentiate into plasma cells, marking a shift away from antigen presentation toward antibody secretion.^[33]^[34]^[35]

Ligands and interactions

Binding to IgE

CD23 functions as the low-affinity receptor for the Fc portion of immunoglobulin E (IgE), with a dissociation constant (K_d) of approximately 10^{-6} to 10^{-7} M for monomeric CD23 binding to IgE.^[36] On B cells, where CD23 is expressed at relatively low density, it primarily binds free monomeric IgE to regulate IgE production. In contrast, on other cell types such as macrophages or epithelial cells, CD23 more effectively engages multimeric IgE, often in the form of IgE-antigen immune complexes, due to enhanced avidity from receptor clustering.^[37]^[38] Recent structural studies have revealed that IgE adopts distinct open and closed conformations, with flexibility in the Cε2-Cε4 domains influencing binding specificity and affinity to CD23.^[39] The primary binding site for IgE resides within the C-type lectin-like domain of CD23, located at the extracellular "head" region. Structural studies, including the 2005 NMR solution structure of the human CD23 lectin domain, reveal that key interactions involve residues such as Arg188, Arg224, Asp227, Glu257, and Tyr189 on CD23, which contribute significantly to the binding interface with the Cε3 domain of IgE.^[9]^[40] On the IgE side, critical residues include Arg376, Lys380, Asp409, and Glu412, which form hydrogen bonds and electrostatic interactions at the Cε3-Cε4 junction. The 2012 crystal structure of the CD23 head domain bound to IgE-Fc further confirms a 2:1 stoichiometry, with two CD23 molecules asymmetrically engaging the IgE dimer without involving carbohydrate recognition typical of lectins.^[41] Notably, despite its C-type lectin domain architecture, IgE binding by CD23 does not require calcium ions, as the interaction interface lacks coordination with metal sites present in classical lectins.^[9] IgE binding to CD23 exhibits temperature sensitivity, with stronger association at lower temperatures such as 4°C compared to 37°C, likely due to reduced conformational dynamics or internalization at physiological temperatures.^[42] Oligomerization of CD23, particularly into trimers on the cell surface, dramatically increases binding avidity to IgE—up to 10-fold higher than monomeric forms—through multivalent interactions that stabilize the complex.^[41] Soluble CD23 (sCD23), generated by proteolytic cleavage of membrane-bound CD23, retains a similar intrinsic affinity for IgE as the monomeric form but promotes IgE transcytosis across epithelial barriers, facilitating antigen delivery without the need for membrane anchoring.^[43]

Interactions with other molecules

CD23 interacts with CD21 (complement receptor 2, CR2) on B cells, forming a co-receptor complex that enhances B-cell activation through association with the ITAM-containing CD19 signaling pathway.^[3] This binding occurs via the lectin domain of CD23 and the short consensus repeats of CD21, allowing CD23 to bridge IgE and CD21 in a ternary complex.^[3] CD23 binds to αv integrins such as αvβ3 and αvβ5, facilitating cell adhesion and supporting interactions with extracellular matrix components. These bindings, which involve an RGD-independent RKC motif in a disulfide-bonded loop at the N-terminus of the CD23 lectin head domain, facilitate cell adhesion and support antigen presentation by immune cells.^[3]^[44] In certain mammalian species, CD23 exhibits glycan-binding activity, recognizing structures such as the disaccharide GlcNAcβ1-2Man, which may contribute to pathogen recognition.^[21] However, this lectin-like function is minimal in humans due to evolutionary mutations in the CD23 gene that abolish sugar-binding capacity, unlike in mice where binding is weaker but present.^[21] Additionally, CD23 forms associations with IgE-CD21 complexes on B cells, promoting efficient transport of IgE without direct interactions with T cells.^[3]

Biological functions

Role in IgE homeostasis

CD23 plays a pivotal role in regulating IgE homeostasis by modulating its synthesis, binding, and clearance through both membrane-bound and soluble forms. Early studies in the 1980s demonstrated that monoclonal antibodies targeting CD23 inhibit IgE production in human B cell cultures stimulated by interleukin-4, establishing CD23 as a key negative regulator of IgE responses in experimental models.^[45] Membrane-bound CD23 on B cells downregulates IgE synthesis through multiple mechanisms. It competes allosterically with the high-affinity IgE receptor FcεRI for binding to free IgE, albeit with lower affinity (K_D ≈ 10^{-7} to 10^{-8} M compared to FcεRI's 10^{-10} to 10^{-11} M), thereby limiting IgE availability for sensitization of effector cells like mast cells and basophils.^[2] Additionally, IgE-immune complexes co-ligate membrane CD23 with CD21 (complement receptor 2) on B cells, inhibiting IgE production by suppressing B cell proliferation.^[2] Soluble CD23 (sCD23), generated by proteolytic cleavage of membrane CD23, functions as a feedback inhibitor in IgE homeostasis. sCD23 binds IgE with moderate affinity, sequestering it from high-affinity receptors such as FcεRI and thereby dampening IgE-mediated immune activation.^[41] Furthermore, membrane-bound CD23 promotes IgE catabolism by facilitating the endocytosis of IgE-immune complexes in antigen-presenting cells, leading to their lysosomal degradation and reducing circulating IgE levels.^[46] Differences between CD23 isoforms influence IgE handling efficiency. The CD23b isoform, predominantly expressed in hematopoietic cells like B cells and dendritic cells, is more efficient at mediating the endocytosis of IgE-antigen complexes compared to CD23a, directing them toward degradation pathways that accelerate IgE clearance.^[47]

Other immunological roles

CD23 plays a multifaceted role in B-cell biology beyond its involvement in IgE regulation. The interaction between membrane-bound CD23 and CD21 (also known as CR2) on the surface of B cells delivers co-stimulatory signals that promote B-cell adhesion.^[3] Soluble CD23 (sCD23), generated through proteolytic cleavage of the membrane form, further sustains the proliferation of activated mature B lymphocytes via autocrine mechanisms and enhances the differentiation of germinal center centroblasts toward the plasma cell lineage, particularly in synergy with cytokines such as IL-1α.^[3] This process is mediated by specific residues in the CD23 stalk region, facilitating homotypic adhesion with a dissociation constant (K_D) of approximately 8.7 × 10⁻⁷ M.^[3] In parallel, CD23 acts as a negative regulator of B-cell receptor (BCR) signaling to prevent excessive B-cell activation and maintain immune homeostasis. Upon BCR engagement, CD23 promotes B-cell contraction and the coalescence of BCR microclusters into central signaling-competent clusters, which dampens downstream signaling pathways.^[48] This regulation involves modulation of actin cytoskeleton reorganization; in the absence of CD23, as observed in CD23 knockout mice, B cells exhibit increased spreading, enhanced actin accumulation, and elevated phosphorylation of key signaling molecules such as Bruton's tyrosine kinase (Btk) and WASP-interacting protein (WIP), leading to hyperactive BCR responses.^[48] These effects occur independently of IgE-immune complexes, underscoring CD23's intrinsic role in fine-tuning B-cell activation thresholds.^[48] CD23 also contributes to antigen capture and presentation by facilitating endocytosis and phagocytosis in key immune cells. On follicular dendritic cells (FDCs), CD23 expression supports the retention and processing of antigens, enabling efficient presentation to cognate B cells within germinal centers through interactions with MHC class II molecules in the CD23 stalk region (residues Glu48 to Lys59).^[3] Similarly, activated macrophages bearing CD23 utilize receptor-mediated endocytosis to internalize antigens, enhancing their phagocytic capacity and subsequent presentation to T cells; this includes roles in antimycobacterial defense where CD23 promotes macrophage activation and pathogen clearance.^[49] CD23-positive B cells further transport captured antigens to splenic follicles, amplifying T- and B-cell responses.^[3] In the context of Th2-biased immune responses, CD23 influences eosinophil survival and activation, as well as broader cytokine modulation. Eosinophils express CD23, and engagement of this receptor on their surface contributes to their activation and prolonged survival in inflammatory environments, supporting eosinophil recruitment and function during type 2 immunity.^[50] Additionally, sCD23 from activated cells induces the production of pro-inflammatory cytokines such as IL-1β and TNF-α by monocytes and macrophages.^[3] CD23 was initially identified as a B-cell activation marker in the context of Epstein-Barr virus (EBV) infection. EBV nuclear antigen 2 (EBNA-2) specifically transactivates CD23 expression in infected B cells, leading to upregulation of the CD23b isoform and contributing to the virus's ability to drive B-cell immortalization and proliferation.^[51] This superinduction of CD23 serves as an early indicator of EBV-mediated B-cell transformation, correlating with the establishment of latency and the outgrowth of lymphoblastoid cell lines.^[52]

Clinical significance

In allergic diseases

CD23 plays a pivotal role in allergic diseases through its cleavage by allergens, which releases soluble CD23 (sCD23) and perturbs IgE homeostasis. The major house dust mite allergen Der p 1, a cysteine protease, specifically cleaves membrane-bound CD23 from the surface of human B cells, generating sCD23 fragments that can upregulate IgE synthesis by disrupting CD23's inhibitory feedback on B-cell activation.^[53] This proteolytic activity enhances the potency of allergens by promoting Th2-skewed immune responses, including increased cytokine production and eosinophil recruitment, thereby exacerbating allergic inflammation in conditions such as asthma and rhinitis.^[46] Elevated sCD23 levels are a hallmark of atopic conditions and strongly correlate with total and allergen-specific IgE concentrations. In patients with atopic dermatitis and asthma, higher serum sCD23 reflects ongoing B-cell activation and is significantly associated with disease severity, as seen in studies of allergic children where sCD23 was markedly increased compared to non-allergic controls.^[54] Recent 2025 research further links CD23 expression on B-lymphocytes to specific IgE against pollen components like Bet v 1 and Phl p 1, showing a stronger correlation in atopic dermatitis patients treated with dupilumab, suggesting CD23's involvement in modulating pollen-induced hypersensitivity.^[55] In food allergies, CD23-expressing IgG1+ memory B cells are particularly relevant, as they are enriched in patients with peanut allergy and poised for class-switch recombination to produce pathogenic IgE. These cells, identified through single-cell RNA sequencing, bear high-affinity receptors for peanut allergens like Ara h 2 and correlate with serum peanut-specific IgE levels, contributing to the persistence of allergic responses.^[18] CD23 dysregulation in asthma is also associated with eosinophilia and impaired lung function. Increased numbers of CD23+IgG1+ B cells in asthmatic patients positively correlate with blood eosinophil counts and inversely with forced expiratory volume in 1 second (FEV1), indicating a role in driving type 2 inflammation and progressive airway obstruction.^[56]

In hematological malignancies

CD23 serves as a valuable immunohistochemical and flow cytometric marker in the diagnosis of several hematological malignancies, particularly in distinguishing B-cell neoplasms based on expression patterns. In chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), CD23 is typically expressed on the surface of neoplastic B cells, with positivity observed in approximately 87% of cases by flow cytometry on peripheral blood mononuclear cells.^[57] This positive expression aids in differentiating CLL/SLL from mantle cell lymphoma (MCL), which is characteristically CD23-negative, thereby facilitating accurate classification in CD5-positive small B-cell lymphoproliferative disorders.^[14] Similarly, CD23 positivity is common in low-grade follicular lymphoma (grades 1-2), where it is detected in up to 83% of cases, further supporting its utility in pathological differentiation from CD23-negative counterparts like MCL.^[58] In mediastinal biopsies, CD23 expression helps distinguish primary mediastinal large B-cell lymphoma (a subtype of diffuse large B-cell lymphoma) from classical Hodgkin lymphoma, with recent analyses confirming its sensitivity of 85% and positive predictive value of 92% as an adjunct marker to histomorphology and other immunostains.^[59] This application remains relevant in 2025 diagnostic workflows for mediastinal masses, where CD23 positivity favors B-cell lymphoma over Hodgkin lymphoma.^[60] Flow cytometry and immunohistochemistry are the primary methods for assessing CD23, with the former particularly effective in CLL where 80-90% of cases show membranous staining on CD19+ CD5+ B cells.^[61] CD23 expression is notably low in multiple myeloma, occurring in only about 10% of plasma cell myeloma cases and specifically associated with chromosome 11 abnormalities.^[62] In certain B-cell neoplasms, such as CLL, low CD23 expression correlates with advanced disease stages, higher white blood cell counts, and bone marrow prolymphocyte infiltration, providing prognostic insights alongside diagnostic value.^[63] These patterns underscore CD23's role as a targeted marker in hematological pathology, enhancing precision in malignancy subtyping without reliance on broader B-cell expression profiles.

Therapeutic implications

Anti-CD23 monoclonal antibodies, such as lumiliximab, have been investigated for their ability to induce apoptosis and antibody-dependent cellular cytotoxicity (ADCC) in chronic lymphocytic leukemia (CLL) cells, which overexpress CD23. In preclinical studies, lumiliximab demonstrated antitumor activity by triggering the intrinsic apoptosis pathway in CD23-positive B cells. Phase I/II trials combining lumiliximab with fludarabine, cyclophosphamide, and rituximab (FCR) in relapsed CLL patients reported an overall response rate of approximately 70% and complete remission in 50% of cases, suggesting enhanced efficacy over FCR alone. However, the phase III LUCID trial, which compared lumiliximab plus FCR to FCR monotherapy in untreated CLL, failed to meet its primary endpoint of progression-free survival improvement, with similar overall response rates (71% vs. 72%) and no significant clinical benefit, leading to discontinuation of development.^[64]^[65]^[66] In allergic diseases, strategies to enhance CD23 function aim to reduce IgE production by promoting membrane-bound CD23's inhibitory role in IgE homeostasis. Combining CD23 modulation with anti-IgE therapies like omalizumab has shown potential for atopic dermatitis management, as omalizumab neutralizes free IgE and may indirectly support CD23-mediated regulation. Studies indicate that dupilumab, an IL-4/IL-13 inhibitor, alters CD23 expression on B cells in atopic dermatitis patients, with higher CD23 levels on switched memory B cells correlating with specific IgE against allergens such as mite components, suggesting CD23's role in IgE regulation that could complement anti-IgE agents.^[67]^[68]^[69] Therapeutic targeting of CD23 is complicated by soluble CD23 (sCD23) forms, which arise from proteolytic shedding and can either inhibit or stimulate IgE synthesis depending on oligomerization, potentially counteracting membrane CD23 effects and reducing antibody specificity. Emerging chimeric antigen receptor (CAR) T-cell approaches indirectly modulate CD23 via B-cell targeting in CLL, where CD23-specific CAR T cells, enhanced by lenalidomide, exhibit potent antileukemic activity in preclinical models without affecting normal B cells.^[70]^[71] Future directions include ADAM10 inhibitors to prevent CD23 shedding, thereby preserving membrane-bound CD23 and suppressing IgE secretion, as demonstrated in vitro where ADAM10 blockade reduced sCD23 release and IgE production in human B cells. Such inhibitors hold promise for allergic disorders by maintaining CD23's negative regulatory function on IgE homeostasis.^[72]^[73]

References

[1]
2208 - Gene ResultFCER2 Fc epsilon receptor II [ (human)] - NCBI
Aug 19, 2025 · CD23 is involved in both up- and down-regulation of IgE; CD23 can bind both its ligands, IgE and CD21, simultaneously. upstream regions of the ...
[2]
The structure of human CD23 and its interactions with IgE and CD21
The low-affinity immunoglobulin E (IgE) receptor, CD23 (FcɛRII), binds both IgE and CD21 and, through these interactions, regulates the synthesis of IgE.
[3]
CD23/FcεRII: molecular multi-tasking - PMC - NIH
CD23 is the low-affinity receptor for immunoglobulin (Ig)E and plays important roles in the regulation of IgE responses. CD23 can be cleaved from cell surfaces ...
[4]
CD23/FcεRII: molecular multi‐tasking - Acharya - Wiley Online Library
Sep 9, 2010 · In humans, CD23 is encoded by an 11-exon gene, FCER2, located at chromosome 19p13.3 [16], in a cluster with the DC-SIGN and DC-SIGNR genes ...<|control11|><|separator|>
[5]
American Journal of Respiratory and Critical Care Medicine
Oct 14, 1998 · The gene encoding CD23 leukocyte antigen (FCER2) is located on human chromosome 19. Somat. Cell Mol. Genet.161990283286. Crossref, Medline ...
[6]
FCER2 (CD23) Asthma-Related Single Nucleotide Polymorphisms ...
Mar 11, 2013 · The R62W SNP, which is located in exon 4 of the FCER2 gene (18), is in the extracellular segment of the protein close to the transmembrane ...
[7]
FCER2 - Low affinity immunoglobulin epsilon Fc receptor - UniProt
FCER2 is a low-affinity receptor for IgE, regulating its production and B cell differentiation. It is a low-affinity receptor, unlike high-affinity receptors.Missing: exons | Show results with:exons
[8]
Fc fragment of IgE receptor II | Fc epsilon receptors
There are three transcript variants of the human FCER2 gene, giving rise to two protein isoforms: FCER2a (321aa) and FCERb (320aa). We provide details for the ...
[9]
The structure of human CD23 and its interactions with IgE and CD21
The results further reveal that CD23 can bind both ligands simultaneously. Despite the C-type lectin domain structure, none of the interactions require calcium.
[10]
Structural changes in the lectin domain of CD23, the low-affinity IgE ...
We have solved the high-resolution crystal structures of the human CD23 lectin domain in the presence and absence of Ca2+. The crystal structures differ ...Missing: Betz 1995
[11]
The CD23a and CD23b proximal promoters display ... - PubMed
The CD23a promoter was activated only by IL-4, whereas the CD23b promoter was stimulated not only by IL-4, but also by stimulation with anti-mu, and anti-CD40.
[12]
CD23 Sheddase A Disintegrin and Metalloproteinase 10 (ADAM10 ...
Soluble CD23 (sCD23) retains IgE-binding ability, although at much lower affinity/avidity than membrane trimeric CD23. In humans, the sCD23 interaction with ...
[13]
The Low Affinity IgE Receptor (CD23) Is Cleaved by the ...
Compared with the control cells, ADAM10-depleted cells produced less of the 37-kDa soluble form of CD23 than the control cells. However, the ADAM10-depleted ...
[14]
CD23 - Pathology Outlines
May 21, 2024 · CD23 is a low affinity IgE receptor found on mature B cells, activated macrophages, eosinophils, follicular dendritic cells, platelets and ...
[15]
CD23 - an overview | ScienceDirect Topics
CD23 is the low-affinity receptor for IgE and is expressed on platelets, eosinophils, activated macrophages, follicular dendritic cells, and mature B cells.
[16]
CD23 expression in activated human T cells is enhanced ... - PubMed
The results demonstrate that IL-7 did not induce CD23 expression in the resting T cells. However, PHA-induced CD23 expression was enhanced by costimulation with ...Missing: plasma monocytes
[17]
Committed Human CD23-Negative Light-Zone Germinal Center B ...
In humans, low expression of the CD23 marker is reported in BGC-cells (16) and LZ BGC-cells (17), and the downregulation of CD23 is associated with PC ...
[18]
CD23+IgG1+ memory B cells are poised to switch to pathogenic IgE ...
Feb 7, 2024 · These cells differentially expressed interleukin-4 (IL-4)– and IL-13–regulated genes, such as FCER2/CD23+, IL4R, and germline IGHE, and carried ...
[19]
Regulation of CD23 isoforms on B-chronic lymphocytic leukemia
CD23 is constitutively and atypically expressed on malignant B-cells in patients with chronic lymphocytic leukemia. It exists in two isoforms that differ only ...
[20]
CD23 Exhibits Negative Regulatory Effects on Allergic Sensitization ...
May 13, 1999 · Although structurally related to the human form, murine CD23 is different in its cellular expression and function. Mouse CD23 is found on B ...
[21]
CD23 is a glycan-binding receptor in some mammalian species - PMC
Although mouse CD23 shows a pattern of monosaccharide and glycoprotein binding similar to cow CD23, the binding is weaker. In contrast, no sugar binding was ...
[22]
Research Upregulation of CD23 (FcεRII) Expression in Human ...
The CD23 receptor has been shown to be upregulated on monocytes and alveolar macrophages in a T helper cell type 2 (TH2) environment and may contribute to ...Missing: profile | Show results with:profile
[23]
STAT6 and the regulation of CD23 expression in B-chronic ...
To elucidate the events controlling CD23 expression in B-CLL cells, the IL-4 mediated induction of STAT6 was investigated. Western-blot analysis demonstrated ...
[24]
STAT6 and the regulation of CD23 expression in B-chronic ...
Whereas IL-4 upregulates CD23 on B-CLL cells to a lower degree than in normal B lymphocytes, IFN-γ significantly enhances the IL-4 induced CD23 expression on B ...
[25]
Interferons inhibit activation of STAT6 by interleukin 4 in human ...
These findings demonstrate that IFNs inhibit IL-4-induced activation of STAT6 and STAT6-dependent gene expression, at least in part, by inducing expression of ...
[26]
IFN-gamma and IFN-alpha posttranscriptionally down-regulate the ...
In particular, IFN-gamma and IFN-alpha have been reported to markedly suppress the IL-4-induced IgE production and type II IgE receptor (FcepsilonRII/CD23) ...
[27]
Interferon-γ Inhibits STAT6 Signal Transduction and Gene ...
Jun 17, 2004 · In this study, we demonstrate that IL-4–induced STAT6 activation was inhibited profoundly by 24 h pretreatment with IFN-γ in human primary ...
[28]
MicroRNA target Fc receptors to regulate Ab-dependent Ag uptake ...
Jul 22, 2016 · However, IFN-γ-induced up-regulation of CD23 expression was significantly reduced in cells overexpressing miR-24, miR-30b and miR-142-3p (Figure ...
[29]
The role of DNA hypomethylation, histone acetylation and in vivo ...
May 24, 2013 · Acetylated histone H3 levels at the CD23b promoter showed strong correlation with CD23b expression, while a weaker correlation could be observed ...
[30]
The role of DNA hypomethylation, histone acetylation and in vivo ...
Our in vivo results suggest a minor role for DNA methylation, while a more important role for histone acetylation in the regulation of EBV-induced CD23 ...
[31]
The Low Affinity IgE Receptor (CD23) Is Cleaved by the ... - NIH
Expression of a mutant metalloproteinase-deficient construct of ADAM10 partially inhibited the production of sCD23. Similarly, small inhibitory RNA knockdown of ...
[32]
CD23 Sheddase A Disintegrin and Metalloproteinase 10 (ADAM10 ...
We found that ADAM10-mediated cleavage was greatly enhanced by CD23 internalization into endosomes and that intact CD23 is incorporated, in an ADAM10-dependent ...
[33]
CD23 defines two distinct subsets of immature B cells which differ in ...
These findings demonstrate that phenotypically defined subsets within the transitional B cell population are functionally distinct.Missing: Betz 1995
[34]
Committed Human CD23-Negative Light-Zone Germinal Center B ...
Dec 2, 2021 · An in-depth analysis (including single-cell gene expression) showed that stimulated CD23-negative LZ BGC-cells differentiated into plasmablasts ...
[35]
activated B cells after the extinction of IL-4/STAT6 signaling and ...
Mar 4, 2021 · Activated B cells that differentiate into plasmablasts downregulate the CD23 marker and IL-4 pathway after an initial IL-4 response. CD23– cells ...
[36]
The mechanistic and functional profile of the therapeutic anti-IgE ...
Jan 8, 2020 · Binding of IgE to monomeric CD23 is of low affinity (KD 10−6–10−7 M). However, cell surface CD23 is prone to oligomerization leading to enhanced ...Results · Ligelizumab Binding... · Engagement Of Cd23:Ige...
[37]
On the complexity of IgE: The role of structural flexibility ... - Frontiers
Mar 27, 2023 · A single CD23 domain binds IgE with a relatively low affinity of KD = 10−6 M (1, 2), however by forming trimers the avidity effect can enhance ...
[38]
https://www.frontiersin.org/journals/allergy/articles/10.3389/falgy.2023.1117611/full
[39]
Crystal structure of IgE bound to its B-cell receptor CD23 ... - PNAS
Jul 16, 2012 · We have solved the crystal structure of the soluble lectin-like “head” domain of CD23 (derCD23) bound to a subfragment of IgE-Fc consisting of the dimer of Cε3 ...
[40]
Temperature effect on IgE binding to CD23 versus Fc epsilon RI
In both systems, the inhibition was found to be temperature dependent; a 10-fold molar excess of lz-CD23 gave 90-98% inhibition at 4 degrees C, dropping to 20- ...
[41]
Inhibition of human interleukin 4-induced IgE synthesis by ... - PubMed
In fact, all the anti-CD23 mAb, except EBVCS#1, were able to inhibit IgE binding to CD23 on RPMI 8866 cells. Moreover, the first set of antibodies, which ...Missing: 1980s paper
[42]
The role of CD23 in the regulation of allergic responses - PMC
We focus on CD23 as an IgE receptor, particularly in the allergic context where CD23 acts as a regulator of IgE levels and modulator of immune responses.
[43]
The role of CD23 in the regulation of allergic responses
Dec 30, 2020 · Apart from its form as a membrane receptor, CD23 can be cleaved into soluble fragments (sCD23) which was studied as a disease marker in allergy, ...
[44]
CD23 can negatively regulate B-cell receptor signaling - Nature
May 16, 2016 · CD23 has been implicated as a negative regulator of IgE and IgG antibody responses. However, whether CD23 has any role in B-cell activation remains unclear.
[45]
https://pubmed.ncbi.nlm.nih.gov/1689660/
[46]
CD23 - an overview | ScienceDirect Topics
RNA splice variants encode 2 isoforms of the protein, CD23a, which is present predominantly on B cells, and CD23b, which is expressed on a wide range of cells, ...
[47]
Epstein-Barr virus nuclear antigen 2 specifically induces expression ...
Since CD23 has been implicated in the transduction of B-cell growth signals, its specific induction by EBNA-2 could be important in EBV induction of B- ...
[48]
https://www.nature.com/articles/srep25629
[49]
Der p I, a major allergen of the house dust mite ... - PubMed
We demonstrate that Der p I, a major allergen of the house dust mite Dermatophagoides pteronyssinus, cleaves CD23 from the surface of cultured human B cells.
[50]
Serum levels of interleukin 4 and soluble CD23 in children with ...
The serum level of soluble CD23 (sCD23) showed an age-dependent change in allergic and non-allergic children and was significantly higher in allergic than in ...
[51]
The interaction between the expression of CD23 molecule on B
May 28, 2025 · This study demonstrated that the relationship between CD23 expression on B-lymphocytes and specific IgE to pollen molecular components varies ...Missing: CD23+ cell
[52]
Intensity of CD23 expression on IgG1+ B cells reflects serum IgE ...
The increased numbers of CD23+IgG1+ B cells in asthma patients are associated with blood eosinophil count and lung function (FEV1), but not with serum IgE ...
[53]
[PDF] CELLULAR EXPRESSION AND SERUM CIRCULATING LEVELS ...
Jul 23, 1996 · Actuarial median survival was 60 months. CD23 was detected on PBMC from 78 out of 90 (86.6%) B-cell CLL patients. In both normal controls and ...
[54]
CD23 expression in follicular lymphoma - Mayo Clinic
Of 69 FLs, 48 (70%) were CD23+. Grade 3 FLs were CD23- more often (12/16 [75%]) than grade 1 and 2 cases (9/53 [17%]; P < .001). CD23 expression was more common ...
[55]
The value of CD23 expression as an additional marker in ... - PubMed
In conclusion CD23 is a useful marker in distinguishing Med-DLBCL and CHL in mediastinal biopsies and may be helpful as an adjunct to histomorphology and other ...
[56]
Primary mediastinal B-cell lymphoma (PMBCL): The LYSA ...
Diffuse EBV positivity in B cells supports the diagnosis of EBV+ DLBCL instead of MGZL or PMBCL. The expression of CD30, CD23, MAL, CD200, or PDL1/2 supports ...
[57]
Differential diagnosis of chronic lymphocytic leukemia/small ... - NIH
Although CLL/SLL has no specific genetic markers, most (80-90%) cases have cytogenetic abnormalities. ... CD23 expression in CLL/SLL is usually high. CD23- ...
[58]
CD23 expression in plasma cell myeloma is specific for ... - PubMed
CD23 expression in plasma cell myeloma is specific for abnormalities of chromosome 11, and is associated with primary plasma cell leukaemia in this cytogenetic ...
[59]
Low CD23 expression correlates with high CD38 expression and ...
Jun 29, 2015 · The correlation of low CD23 expression with prolymphocyte infiltration of the bone marrow (BM), white blood cell count, and stages of disease ...
[60]
Mediation of apoptosis by and antitumor activity of lumiliximab in ...
Feb 1, 2008 · Our data suggest that lumiliximab kills CLL cells and CD23-expressing B cells predominantly by apoptosis, which occurs through the intrinsic pathway.Missing: implications | Show results with:implications
[61]
Lumiliximab in combination with FCR for the treatment of relapsed ...
Background: Lumiliximab is an anti-CD23 monoclonal antibody that is being investigated for the treatment of relapsed B-cell CLL (BCLL).Missing: implications trials
[62]
A randomized, open-label, multicentre, phase 2/3 study to ... - PubMed
Aug 8, 2014 · Overall the combination of lumiliximab with FCR was not significantly better than FCR alone (overall response rate 71% vs. 72%, complete ...Missing: results | Show results with:results<|separator|>
[63]
CD23 Levels on B Cells Determine Long-Term Therapeutic ...
By means of these findings, we suggest that CD23 is a regulator of long-term type 2 immune responses and can be used as an early biomarker in determining ...
[64]
The association between the level of specific IgE to molecular ... - NIH
Jul 22, 2023 · The CD23 molecule has an effect on the regulation of IgE synthesis, either by stimulation or inhibition. It is not yet known whether the ...
[65]
Interaction between expression of CD23 on B-lymphocytes and level ...
CD23 primarily functions as a low-affinity IgE receptor, regulating IgE homeostasis through various pathways. Increased CD23 expression on B-cells could enhance ...
[66]
Soluble CD23 Monomers Inhibit and Oligomers Stimulate IGE ...
In addition to the soluble fragments, there are two forms of CD23 that can be expressed in the cell membrane. CD23a and CD23b differ by 6 or 7 amino acids ...
[67]
Lenalidomide enhances CD23.CAR T cell therapy in chronic ...
Abstract. Chimeric antigen receptors (CAR)-modified T cells are an emerging therapeutic tool for chronic lymphocytic leukemia (CLL).
[68]
Soluble CD23 Controls IgE Synthesis and Homeostasis in Human B ...
Soluble CD23 fragments are released from membrane CD23 by the endogenous metalloprotease, ADAM10 ... forms biologically active complexes with CD23: sCD21 ...
[69]
A Potential New Target for Asthma Therapy: A Disintegrin and ... - NIH
Elevated levels of CD23, a natural regulator of IgE production, have been shown to decrease the signs of lung inflammation in mice.